{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:38:31Z","timestamp":1792787911331,"version":"4.5.0"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,12,18]],"date-time":"2021-12-18T00:00:00Z","timestamp":1639785600000},"content-version":"vor","delay-in-days":17,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"national natural science foundation of china","doi-asserted-by":"publisher","award":["81602411"],"award-info":[{"award-number":["81602411"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"national natural science foundation of china","doi-asserted-by":"publisher","award":["81772518"],"award-info":[{"award-number":["81772518"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013105","name":"shanghai rising-star program","doi-asserted-by":"publisher","award":["20QA1406200"],"award-info":[{"award-number":["20QA1406200"]}],"id":[{"id":"10.13039\/501100013105","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008410","name":"shanghai municipal population and family planning commission","doi-asserted-by":"publisher","award":["20184Y0048"],"award-info":[{"award-number":["20184Y0048"]}],"id":[{"id":"10.13039\/501100008410","id-type":"DOI","asserted-by":"publisher"}]},{"name":"guangci distinguished young scholars training program","award":["GCQN-2018-A06"],"award-info":[{"award-number":["GCQN-2018-A06"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>In this study, we tried to access the efficacy and safety of oxaliplatin plus S-1 with intraperitoneal paclitaxel (PTX) for the treatment of Chinese advanced gastric cancer with peritoneal metastases.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patients and methods<\/jats:title>\n                    <jats:p>\n                      Thirty patients diagnosed with advanced gastric cancer underwent laparoscopic exploration and were enrolled when macroscopic disseminated metastases (P1) were confirmed. PTX was diluted in 1\u2009l of normal saline and IP administered through peritoneal port at an initial dose of 40\u2009mg\/m\n                      <jats:sup>2<\/jats:sup>\n                      over 1\u2009h on day1,8, respectively. Oxaliplatin was administered intravenously at an initial dose of 100\u2009mg\/m\n                      <jats:sup>2<\/jats:sup>\n                      on day1, and S-1 was administered orally at an initial dose of 80\u2009mg\/m\n                      <jats:sup>2<\/jats:sup>\n                      for 14\u2009days followed by 7\u2009days rest, repeated by every 3\u2009weeks.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Of all these 30 patients, the median number of cycles was 6 (range 2\u201316) due to the limitation of hematotoxicity and peripheral neuropathy by oxaliplatin. There were 11 (36.7%) patients received conversion surgery. The median progression free survival (PFS) was 6.6\u2009months (95% CI\u2009=\u20094.7\u20138.5\u2009months) and the median overall survival (OS) was 15.1\u2009months (95% CI\u2009=\u200912.4\u201317.8\u2009months). The grade 3\u20134 hematological toxicities were leucopenia (23.3%), neutropenia (23.3%), anemia (16.7%), and thrombocytopenia (20%), respectively. The grade 3\u20134 non-hematological toxicities were tolerated, most of which were peripheral sensory neuropathy (40%) due to oxaliplatin, diarrhea (20%), nausea and vomiting (26.7%).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>SOX+ip PTX regimen was effective in advanced gastric cancer with peritoneal metastasis. Survival time was significantly prolonged by conversion surgery. Grade 3\u20134 toxicities were uncommon. Large scale clinical trial is necessary to get more evidence to identify its efficacy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trail registration<\/jats:title>\n                    <jats:p>\n                      ChiCTR,\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/www.chictr.org.cn\/showproj.aspx?proj=15613\">ChiCTR-IIR-16009802<\/jats:ext-link>\n                      . Registered 9 November 2016,\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12885-021-09027-5","type":"journal-article","created":{"date-parts":[[2021,12,18]],"date-time":"2021-12-18T07:02:37Z","timestamp":1639810957000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Oxaliplatin plus S-1 with intraperitoneal paclitaxel for the treatment of Chinese advanced gastric cancer with peritoneal metastases"],"prefix":"10.1186","volume":"21","author":[{"given":"Min","family":"Shi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhongyin","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheng","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wentao","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhentian","family":"Ni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuexin","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zichen","family":"Hua","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Runhua","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanan","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenqiang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Birendra Kumar","family":"Sah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingmin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenglun","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Changyu","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenggang","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,12,18]]},"reference":[{"issue":"6","key":"9027_CR1","doi-asserted-by":"crossref","first-page":"394","DOI":"10.3322\/caac.21492","volume":"68","author":"F Bray","year":"2018","unstructured":"Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394\u2013424.","journal-title":"CA Cancer J Clin"},{"issue":"10060","key":"9027_CR2","doi-asserted-by":"publisher","first-page":"2606","DOI":"10.1016\/S0140-6736(16)32226-7","volume":"388","author":"L Zong","year":"2016","unstructured":"Zong L, Abe M, Seto Y, Ji J. The challenge of screening for early gastric cancer in China. Lancet. 2016;388(10060):2606.","journal-title":"Lancet"},{"issue":"8","key":"9027_CR3","doi-asserted-by":"publisher","first-page":"1921","DOI":"10.1002\/ijc.29227","volume":"136","author":"H Zeng","year":"2015","unstructured":"Zeng H, Zheng R, Guo Y, Zhang S, Zou X, Wang N, et al. Cancer survival in China, 2003-2005: a population-based study. Int J Cancer. 2015;136(8):1921\u201330.","journal-title":"Int J Cancer"},{"issue":"5","key":"9027_CR4","first-page":"1133","volume":"69","author":"JC Layke","year":"2004","unstructured":"Layke JC, Lopez PP. Gastric cancer: diagnosis and treatment options. Am Fam Physician. 2004;69(5):1133\u201340.","journal-title":"Am Fam Physician"},{"issue":"6","key":"9027_CR5","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1016\/j.ejso.2006.03.003","volume":"32","author":"Y Yonemura","year":"2006","unstructured":"Yonemura Y, Bandou E, Kawamura T, Endou Y, Sasaki T. Quantitative prognostic indicators of peritoneal dissemination of gastric cancer. Eur J Surg Oncol. 2006;32(6):602\u20136.","journal-title":"Eur J Surg Oncol"},{"issue":"1","key":"9027_CR6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s10120-012-0163-4","volume":"16","author":"A Nashimoto","year":"2013","unstructured":"Nashimoto A, Akazawa K, Isobe Y, Miyashiro I, Katai H, Kodera Y, et al. Gastric cancer treated in 2002 in Japan: 2009 annual report of the JGCA nationwide registry. Gastric Cancer. 2013;16(1):1\u201327.","journal-title":"Gastric Cancer"},{"issue":"1","key":"9027_CR7","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.ejso.2013.10.019","volume":"40","author":"F Coccolini","year":"2014","unstructured":"Coccolini F, Cotte E, Glehen O, Lotti M, Poiasina E, Catena F, et al. Intraperitoneal chemotherapy in advanced gastric cancer. Meta-analysis of randomized trials. Eur J Surg Oncol. 2014;40(1):12\u201326.","journal-title":"Eur J Surg Oncol"},{"issue":"33","key":"9027_CR8","doi-asserted-by":"publisher","first-page":"7478","DOI":"10.3748\/wjg.v22.i33.7478","volume":"22","author":"J Wei","year":"2016","unstructured":"Wei J, Wu ND, Liu BR. Regional but fatal: Intraperitoneal metastasis in gastric cancer. World J Gastroenterol. 2016;22(33):7478\u201385.","journal-title":"World J Gastroenterol"},{"key":"9027_CR9","first-page":"11","volume":"169","author":"Y Yonemura","year":"2007","unstructured":"Yonemura Y, Kawamura T, Bandou E, Tsukiyama G, Endou Y, Miura M. The natural history of free cancer cells in the peritoneal cavity. Recent Results Cancer Res. 2007;169:11\u201323.","journal-title":"Recent Results Cancer Res"},{"issue":"6","key":"9027_CR10","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1038\/nrc1098","volume":"3","author":"IJ Fidler","year":"2003","unstructured":"Fidler IJ. The pathogenesis of cancer metastasis: the 'seed and soil' hypothesis revisited. Nat Rev Cancer. 2003;3(6):453\u20138.","journal-title":"Nat Rev Cancer"},{"issue":"11","key":"9027_CR11","doi-asserted-by":"publisher","first-page":"2541","DOI":"10.1002\/cncr.32868","volume":"126","author":"Chicago Consensus Working Group","year":"2020","unstructured":"Chicago Consensus Working Group. The Chicago consensus on peritoneal surface malignancies: management of gastric metastases. Cancer. 2020;126(11):2541\u20136.","journal-title":"Cancer"},{"issue":"31","key":"9027_CR12","doi-asserted-by":"publisher","first-page":"4991","DOI":"10.1200\/JCO.2006.06.8429","volume":"24","author":"E Van Cutsem","year":"2006","unstructured":"Van Cutsem E, Moiseyenko VM, Tjulandin S, Majlis A, Constenla M, Boni C, et al. Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 study group. J Clin Oncol. 2006;24(31):4991\u20137.","journal-title":"J Clin Oncol"},{"issue":"1","key":"9027_CR13","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1056\/NEJMoa073149","volume":"358","author":"D Cunningham","year":"2008","unstructured":"Cunningham D, Starling N, Rao S, Iveson T, Nicolson M, Coxon F, et al. Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med. 2008;358(1):36\u201346.","journal-title":"N Engl J Med"},{"issue":"11","key":"9027_CR14","doi-asserted-by":"publisher","first-page":"1882","DOI":"10.1093\/annonc\/mdn403","volume":"19","author":"SE Al-Batran","year":"2008","unstructured":"Al-Batran SE, Hartmann JT, Hofheinz R, Homann N, Rethwisch V, Probst S, et al. Biweekly fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) for patients with metastatic adenocarcinoma of the stomach or esophagogastric junction: a phase II trial of the Arbeitsgemeinschaft Internistische Onkologie. Ann Oncol. 2008;19(11):1882\u20137.","journal-title":"Ann Oncol"},{"issue":"3","key":"9027_CR15","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1080\/02841860600791483","volume":"46","author":"SY Oh","year":"2007","unstructured":"Oh SY, Kwon HC, Seo BG, Kim SH, Kim JS, Kim HJ. A phase II study of oxaliplatin with low dose leucovorin and bolus and continuous infusion 5-fluorouracil (modified FOLFOX-4) as first line therapy for patients with advanced gastric cancer. Acta Oncol. 2007;46(3):336\u201341.","journal-title":"Acta Oncol"},{"issue":"3","key":"9027_CR16","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1007\/s10120-009-0517-8","volume":"12","author":"M Imazawa","year":"2009","unstructured":"Imazawa M, Kojima T, Boku N, Onozawa Y, Hironaka S, Fukutomi A, et al. Efficacy of sequential methotrexate and 5-fluorouracil (MTX\/5FU) in improving oral intake in patients with advanced gastric cancer with severe peritoneal dissemination. Gastric Cancer. 2009;12(3):153\u20137.","journal-title":"Gastric Cancer"},{"issue":"10","key":"9027_CR17","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1093\/jjco\/hyt114","volume":"43","author":"K Shirao","year":"2013","unstructured":"Shirao K, Boku N, Yamada Y, Yamaguchi K, Doi T, Goto M, et al. Randomized phase III study of 5-fluorouracil continuous infusion vs. sequential methotrexate and 5-fluorouracil therapy in far advanced gastric cancer with peritoneal metastasis (JCOG0106). Jpn J Clin Oncol. 2013;43(10):972\u201380.","journal-title":"Jpn J Clin Oncol"},{"key":"9027_CR18","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1007\/978-1-4613-1247-5_4","volume":"82","author":"P Jacquet","year":"1996","unstructured":"Jacquet P, Sugarbaker PH. Peritoneal-plasma barrier. Cancer Treat Res. 1996;82:53\u201363.","journal-title":"Cancer Treat Res"},{"issue":"9","key":"9027_CR19","doi-asserted-by":"publisher","first-page":"2370","DOI":"10.1245\/s10434-010-1039-7","volume":"17","author":"O Glehen","year":"2010","unstructured":"Glehen O, Gilly FN, Arvieux C, Cotte E, Boutitie F, Mansvelt B, et al. Peritoneal carcinomatosis from gastric cancer: a multi-institutional study of 159 patients treated by cytoreductive surgery combined with perioperative intraperitoneal chemotherapy. Ann Surg Oncol. 2010;17(9):2370\u20137.","journal-title":"Ann Surg Oncol"},{"issue":"8","key":"9027_CR20","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1016\/j.ejso.2016.03.016","volume":"42","author":"Y Yonemura","year":"2016","unstructured":"Yonemura Y, Canbay E, Li Y, Coccolini F, Glehen O, Sugarbaker PH, et al. A comprehensive treatment for peritoneal metastases from gastric cancer with curative intent. Eur J Surg Oncol. 2016;42(8):1123\u201331.","journal-title":"Eur J Surg Oncol"},{"issue":"2","key":"9027_CR21","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1245\/s10434-013-3208-y","volume":"21","author":"J Kitayama","year":"2014","unstructured":"Kitayama J, Ishigami H, Yamaguchi H, Yamashita H, Emoto S, Kaisaki S, et al. Salvage gastrectomy after intravenous and intraperitoneal paclitaxel (PTX) administration with oral S-1 for peritoneal dissemination of advanced gastric cancer with malignant ascites. Ann Surg Oncol. 2014;21(2):539\u201346.","journal-title":"Ann Surg Oncol"},{"issue":"13","key":"9027_CR22","doi-asserted-by":"publisher","first-page":"3726","DOI":"10.1245\/s10434-011-1770-8","volume":"18","author":"Y Fujiwara","year":"2011","unstructured":"Fujiwara Y, Takiguchi S, Nakajima K, Miyata H, Yamasaki M, Kurokawa Y, et al. Neoadjuvant intraperitoneal and systemic chemotherapy for gastric cancer patients with peritoneal dissemination. Ann Surg Oncol. 2011;18(13):3726\u201331.","journal-title":"Ann Surg Oncol"},{"issue":"19","key":"9027_CR23","doi-asserted-by":"publisher","first-page":"1922","DOI":"10.1200\/JCO.2018.77.8613","volume":"36","author":"H Ishigami","year":"2018","unstructured":"Ishigami H, Fujiwara Y, Fukushima R, Nashimoto A, Yabusaki H, Imano M, et al. Phase III trial comparing Intraperitoneal and intravenous paclitaxel plus S-1 versus Cisplatin plus S-1 in patients with gastric cancer with peritoneal metastasis: PHOENIX-GC trial. J Clin Oncol. 2018;36(19):1922\u20139.","journal-title":"J Clin Oncol"},{"key":"9027_CR24","doi-asserted-by":"crossref","unstructured":"Saito S, Yamaguchi H, Ohzawa H, Miyato H, Kanamaru R, Kurashina K, et al. Intraperitoneal Administration of Paclitaxel Combined with S-1 plus Oxaliplatin as induction therapy for patients with advanced gastric cancer with peritoneal metastases. Ann Surg Oncol. 2020;28(7):3863-70.","DOI":"10.1245\/s10434-020-09388-4"},{"issue":"3","key":"9027_CR25","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","volume":"92","author":"P Therasse","year":"2000","unstructured":"Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000;92(3):205\u201316.","journal-title":"J Natl Cancer Inst"},{"issue":"2","key":"9027_CR26","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1007\/s10120-011-0041-5","volume":"14","author":"Japanese Gastric Cancer Association","year":"2011","unstructured":"Japanese Gastric Cancer Association. Japanese gastric cancer a: Japanese classification of gastric carcinoma: 3rd English edition. Gastric Cancer. 2011;14(2):101\u201312.","journal-title":"Gastric Cancer"},{"issue":"1","key":"9027_CR27","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.ad.2019.05.009","volume":"112","author":"A Freites-Martinez","year":"2021","unstructured":"Freites-Martinez A, Santana N, Arias-Santiago S, Viera A. Using the common terminology criteria for adverse events (CTCAE - version 5.0) to evaluate the severity of adverse events of anticancer therapies. Actas Dermosifiliogr (Engl Ed). 2021;112(1):90\u20132.","journal-title":"Actas Dermosifiliogr (Engl Ed)"},{"issue":"4","key":"9027_CR28","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1002\/jso.21324","volume":"100","author":"Y Yonemura","year":"2009","unstructured":"Yonemura Y, Endou Y, Shinbo M, Sasaki T, Hirano M, Mizumoto A, et al. Safety and efficacy of bidirectional chemotherapy for treatment of patients with peritoneal dissemination from gastric cancer: selection for cytoreductive surgery. J Surg Oncol. 2009;100(4):311\u20136.","journal-title":"J Surg Oncol"},{"issue":"Suppl 1","key":"9027_CR29","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1007\/s10120-016-0684-3","volume":"20","author":"H Ishigami","year":"2017","unstructured":"Ishigami H, Yamaguchi H, Yamashita H, Asakage M, Kitayama J. Surgery after intraperitoneal and systemic chemotherapy for gastric cancer with peritoneal metastasis or positive peritoneal cytology findings. Gastric Cancer. 2017;20(Suppl 1):128\u201334.","journal-title":"Gastric Cancer"},{"issue":"6","key":"9027_CR30","doi-asserted-by":"publisher","first-page":"1575","DOI":"10.1245\/s10434-011-1631-5","volume":"18","author":"XJ Yang","year":"2011","unstructured":"Yang XJ, Huang CQ, Suo T, Mei LJ, Yang GL, Cheng FL, et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy improves survival of patients with peritoneal carcinomatosis from gastric cancer: final results of a phase III randomized clinical trial. Ann Surg Oncol. 2011;18(6):1575\u201381.","journal-title":"Ann Surg Oncol"},{"issue":"3","key":"9027_CR31","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/S1470-2045(08)70035-4","volume":"9","author":"W Koizumi","year":"2008","unstructured":"Koizumi W, Narahara H, Hara T, Takagane A, Akiya T, Takagi M, et al. S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial. Lancet Oncol. 2008;9(3):215\u201321.","journal-title":"Lancet Oncol"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-021-09027-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-021-09027-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-021-09027-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,18]],"date-time":"2021-12-18T19:05:29Z","timestamp":1639854329000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-021-09027-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12]]},"references-count":31,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["9027"],"URL":"https:\/\/doi.org\/10.1186\/s12885-021-09027-5","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,12]]},"assertion":[{"value":"14 July 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 November 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 December 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Ethics committee of Ruijin Hospital, Shanghai Jiaotong University School of Medicine. Written informed consent was obtained from all patients prior to enrollment according to the Declaration of Helsinki. This study was registered in China Clinical Trial Registry (ChiCTR-IIR-16009802).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1344"}}